Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
91.37
+1.05 (+1.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biomarin Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
Next >
Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart
November 24, 2021
If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not...
Via
Benzinga
Where Biomarin Pharmaceutical Stands With Analysts
November 22, 2021
Over the past 3 months, 6 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021
November 22, 2021
Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE:
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Exposures
COVID-19
10 Biggest Price Target Changes For Monday
November 22, 2021
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A...
Via
Benzinga
Why BioMarin Pharmaceutical Stock Jumped by 10.3% on Friday
November 20, 2021
The rare-disease specialist might now have a true franchise-level drug following the approval of Voxzogo.
Via
The Motley Fool
Exposures
Product Safety
BioMarin Stock Jumps As FDA Approval Unlocks Its 'Next Growth Inflection'
November 19, 2021
The BioMarin drug treats achondroplasia, a form of short-limbed dwarfism.
Via
Investor's Business Daily
Exposures
Product Safety
FDA Conditionally Approves Biomarin's Dwarfism Drug
November 19, 2021
The FDA has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) for Injection for achondroplasia. The approval comes for achondroplasia...
Via
Benzinga
Exposures
Product Safety
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...
Via
Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
November 14, 2021
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...
Via
Benzinga
Exposures
Product Safety
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
November 02, 2021
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...
Via
Benzinga
BioMarin's Q3 Net Income Hit By Lower Product Sales
October 28, 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 14% Y/Y decrease in Q3 revenue to $408.7 million, missing the consensus estimate of $435.32 million. The decline...
Via
Benzinga
BioMarin Pharmaceutical inc (BMRN) Q3 2021 Earnings Call Transcript
October 28, 2021
BMRN earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biomarin Pharmaceutical: Q3 Earnings Insights
October 27, 2021
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 27, 2021 at 04:05 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More
October 16, 2021
This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll. Other featured articles discuss which companies may benefit...
Via
Benzinga
Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug
September 09, 2021
Stifel
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
Price To Earnings Ratio Insights For Biomarin Pharmaceutical
September 07, 2021
In the current market session, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is trading at $80.65, after a 5.06% drop. However, over the past month, the stock spiked by...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 07, 2021
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021
September 09, 2021
Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE:
Via
Benzinga
FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder
September 07, 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) faces another setback in its gene therapy development program after the FDA placed the phenylketonuria (PKU) gene...
Via
Benzinga
Exposures
Product Safety
Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval
August 27, 2021
The European Commission (EC) has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) once-daily injection to treat achondroplasia. The...
Via
Benzinga
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
August 20, 2021
All it will take is an FDA approval and a partial repeat of history.
Via
The Motley Fool
Exposures
Product Safety
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
July 29, 2021
BioMarin Pharmaceutical Inc reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues,...
Via
Talk Markets
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
July 29, 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to...
Via
Benzinga
BioMarin Pharmaceutical inc (BMRN) Q2 2021 Earnings Call Transcript
July 29, 2021
BMRN earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biomarin Pharmaceutical: Q2 Earnings Insights
July 28, 2021
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 143.75% over the...
Via
Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...
Via
Benzinga
Exposures
Product Safety
BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy
July 21, 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced new data from open-label Phase 1/2 trial of valoctocogene roxaparvovec, an investigational gene therapy...
Via
Benzinga
BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22
July 15, 2021
The European Medicines Agency (EMA) has validated BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) marketing application seeking approval for hemophilia A gene...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.